W
WAVEMAN · COMPANY
NTRA · Natera, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

NTRA

Natera, Inc.
HEALTHCARE SERVICES · SERVICES-MEDICAL LABORATORIES · CIK 0001604821
CONGRESS · 1FORM 144 · 38☆ WATCH
INSIDER NET · 180D
-$145.5M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
1
FUNDS ADDED · QTR
514
13F, latest reported quarter
REVENUE GROWTH
+35.9%
XBRL, annual
NET MARGIN
-9.0%
CONVERSIONS · 180D
6
codes C/M, not in net · $3.1M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$145.5M over 180 days
-$63.8M over 90 days
below 91% of Healthcare Services
CONGRESS
1 member bought in the last year
the lowest in Healthcare Services
FUNDS
514 funds added or opened last quarter
more than 97% of Healthcare Services
REVENUE
+35.9% year over year
more than 84% of Healthcare Services
MARGIN
-9.0% net margin
below 72% of Healthcare Services
BUYBACKS
no share repurchases reported
SHORT
3.0% of shares outstanding short · 4.7 days to cover · settled 2026-07-31
more than 52% of Healthcare Services
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$145.5M across 11 people in 180 days.
514 funds added or opened positions in the latest 13F quarter, of 848 holders.
1 member of Congress reported buying it this year.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +93.8%
+93.8%12M
-5%+30%+65%+100%2025-092025-102025-122026-032026-052026-072026-09 2025-11-03 · Chapman Steven Leonard sold $31.3M2026-01-20 · Chapman Steven Leonard sold $16.9M2026-02-02 · Chapman Steven Leonard sold $9.6M2026-01-21 · Brophy Michael Burkes sold $8.9M2026-06-01 · BOTHA ROELOF sold $5.8M2026-01-20 · Brophy Michael Burkes sold $5.6M2026-01-20 · Moshkevich Solomon sold $5.4M2025-12-12 · ROSENMAN HERM sold $5.0M2026-09-02 · Moshkevich Solomon sold $5.0M2026-03-16 · Rabinowitz Matthew sold $4.9M2026-06-01 · BOTHA ROELOF sold $4.7M2026-02-02 · Chapman Steven Leonard sold $4.6M2026-01-20 · RABINOWITZ DANIEL sold $4.5M2025-11-24 · BOTHA ROELOF sold $4.5M2025-09-19 · Rabinowitz Matthew sold $4.4M2026-03-12 · Rabinowitz Matthew sold $4.2M2026-01-20 · Fesko John sold $4.2M2026-06-24 · ROSENMAN HERM sold $4.1M2026-03-13 · Rabinowitz Matthew sold $4.1M2026-06-24 · RABINOWITZ DANIEL sold $4.1M2026-03-13 · Rabinowitz Matthew sold $4.0M2025-11-24 · BOTHA ROELOF sold $3.6M2025-11-04 · Rabinowitz Matthew sold $3.4M2025-11-03 · Rabinowitz Matthew sold $3.4M2026-06-01 · BOTHA ROELOF sold $3.3M2025-12-12 · ROSENMAN HERM sold $3.3M2026-03-16 · Rabinowitz Matthew sold $3.2M2026-03-13 · Rabinowitz Matthew sold $3.2M2026-06-24 · RABINOWITZ DANIEL sold $2.8M2025-12-12 · ROSENMAN HERM sold $2.7M2026-03-13 · Rabinowitz Matthew sold $2.6M2025-09-18 · Rabinowitz Matthew sold $2.6M2026-06-12 · Rabinowitz Matthew sold $2.6M2026-06-15 · Rabinowitz Matthew sold $2.6M2025-11-24 · BOTHA ROELOF sold $2.3M2025-11-24 · BOTHA ROELOF sold $2.3M2025-11-20 · Sheena Jonathan sold $2.3M2026-06-01 · BOTHA ROELOF sold $2.2M2026-06-15 · Rabinowitz Matthew sold $2.2M2026-02-02 · Chapman Steven Leonard sold $2.1M2026-08-10 · Fesko John sold $2.1M2026-08-10 · Sheena Jonathan sold $2.0M2026-09-02 · SOLOMON MOSHKEVICH filed to sell $02026-09-01 · STEVEN L CHAPMAN filed to sell $545.0K2026-09-01 · SOLOMON MOSHKEVICH filed to sell $962.2K2026-08-07 · Sheena Jonathan filed to sell $6.0M2026-08-07 · TINKERBELLE II TR U/A DTD 10/22/2021 filed to sell $641.8K2026-08-04 · MICHAEL BROPHY filed to sell $129.2K2026-08-03 · MICHAEL BROPHY filed to sell $83.8K2026-08-03 · STEVEN CHAPMAN filed to sell $312.5K2026-08-03 · STEVEN L CHAPMAN filed to sell $502.7K2026-08-03 · JOHN FESKO filed to sell $78.2K2026-08-03 · SOLOMON MOSHKEVICH filed to sell $795.8K2026-08-03 · SOLOMON MOSHKEVICH filed to sell $108.4K2026-08-03 · MATTHEW RABINOWITZ filed to sell $193.3K2026-08-03 · JONATHAN SHEENA filed to sell $28.9K2026-08-03 · DANIEL RABINOWITZ filed to sell $88.4K2026-07-29 · MICHAEL BROPHY filed to sell $469.9K2026-07-28 · MICHAEL BROPHY filed to sell $315.3K2026-07-28 · MICHAEL BROPHY filed to sell $304.0K2026-07-28 · STEVEN CHAPMAN filed to sell $909.6K2026-07-28 · JOH N FESKO filed to sell $236.6K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $145.5M sold by insiders over 180 days, 514 funds added last quarter, 1 Congress member(s) bought in 12 months, $35.9M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
CSTLPGNYHIMSWGSPRVATDOCAVAHGHADUSSERABDSXENSG
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Natera, Inc. insiders sold a net $145.5M of stock across 1,335 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Moshkevich Solomon
PRESIDENT, CLINICALDIAGNOSTICS
SELL
2026-09-02
15,160.0
$5.0M
Chapman Steven Leonard
CEO AND PRESIDENT
SELL
2026-09-01
1,698.0
$545.0K
Moshkevich Solomon
PRESIDENT, CLINICALDIAGNOSTICS
SELL
2026-09-01
1,000.0
$319.8K
Moshkevich Solomon
PRESIDENT, CLINICALDIAGNOSTICS
SELL
2026-09-01
1,400.0
$449.3K
Moshkevich Solomon
PRESIDENT, CLINICALDIAGNOSTICS
SELL
2026-09-01
600.0
$193.1K
1,335 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 1,330 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
JPMORGAN CHASE & CO
12,865,346.0 sh
$3.5B
BlackRock, Inc.
10,914,608.0 sh
$3.0B
VANGUARD CAPITAL MANAGEMENT LLC
6,228,216.0 sh
$1.7B
VANGUARD PORTFOLIO MANAGEMENT LLC
5,782,640.0 sh
$1.6B
FMR LLC
5,451,396.0 sh
$1.5B
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
SOLOMON MOSHKEVICH
FILED 2026-09-02
$0
STEVEN L CHAPMAN
FILED 2026-09-01
$545.0K
SOLOMON MOSHKEVICH
FILED 2026-09-01
$962.2K
Sheena Jonathan
FILED 2026-08-07
$6.0M
TINKERBELLE II TR U/A DTD 10/22/2021
FILED 2026-08-07
$641.8K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Paradigm Select Fund
$11.9M POSITION · AS OF 2026-03-31
8.5%
Franklin Genomic Advancements ETF
$1.4M POSITION · AS OF 2026-03-31
6.6%
TrueShares Technology, AI & Deep Learning ETF
$1.3M POSITION · AS OF 2026-03-31
4.5%
ARK Genomic Revolution ETF
$50.2M POSITION · AS OF 2026-04-30
4.1%
VanEck Biotech ETF
$14.8M POSITION · AS OF 2026-03-31
4.0%
Global X Genomics & Biotechnology ETF
$2.0M POSITION · AS OF 2026-02-28
3.9%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 24 registered trials, 15 still enrolling or running — a status change here is dated weeks before the press release
24
Not applicable
15 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Corporate PAC
FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors
Natera, Inc. Pac (Natera Pac)
CYCLE 2026 · $69K SPENT
$95.0K
FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION
Executive pay vs shareholder return
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$15.0M
$60.8M
$6.8M
+130%
+25%
2024
$13.0M
$95.4M
$6.1M
+59%
-7%
2023
$12.7M
$32.8M
$4.9M
-37%
-6%
2022
$8.2M
-$10.5M
$4.5M
-60%
-10%
2021
$23.3M
$17.8M
$8.4M
-6%
+0%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$2.3B$1.7B$1.1B$820.2M
OPERATING INCOME$-309.9M$-222.3M$-446.2M$-541.0M
NET INCOME$-208.2M$-190.4M$-434.8M$-547.8M
EPS (DILUTED)-1.52-1.53-3.78-5.57
OPERATING CASH FLOW$215.3M$135.7M$-247.0M$-431.5M
CASH———$466.0M
LONG-TERM DEBT——$282.9M$281.7M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →